Compare AbbVie Inc (ABBV) vs Fox Corp Class B (FOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Fox Corp Class B — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Fox Corp Class B trades at $48.03 (market cap $21.80B). The key difference: AbbVie Inc is far larger — about 20.6× Fox Corp Class B's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | FOX | |
|---|---|---|
Market Cap | $449.91B | $21.80B |
Sector | Health | Media |
52-Week High | $261.07 | $67.76 |
52-Week Low | $184.85 | $44.39 |
Enterprise Value | $513.38B | $25.77B |
Dividend Yield | 2.72% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
FOX stock trades at $49.20, down 2.69% on the day, amid bearish technical signals and recent volatility following its $22 billion Roku acquisition announcement. The company shows strong fundamental performance with three consecutive quarterly earnings beats, revenue growth to $16.3 billion in 2025, and improved cash flow generation. However, technical indicators signal bearish momentum with the stock trading near support levels while analyst sentiment remains mixed with 43% buy ratings.
The outlook balances strong operational execution against acquisition integration risks. FOX's attractive valuation (P/E 13.14) and streaming expansion through Roku present growth opportunities, but high leverage and competitive pressures create near-term uncertainty. Investor focus remains on Q2 2026 earnings delivery and Roku synergy realization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
